Hemab Therapeutics Inc. (NASDAQ:COAG) on Sunday presented new clinical data for its lead candidate HMB-002 in Von Willebrand disease (VWD) and introduced HMB-003, a new program targeting heavy menstrual bleeding, at the International Society on Thrombosis and Hemostasis (ISTH) 2026 Congress.
The company said the latest findings support its strategy of addressing the underlying biology of bleeding disorders rather than relying on traditional replacement therapies.
• Hemab Therapeutics stock is at critical resistance. What’s behind COAG new highs?
HMB-002 Shows Early Signs Of Potential In VWD
According to Benny Sørensen, CEO of Hemab, the latest HMB-002 data demonstrated proof of mechanism in VWD and included preliminary clinical observations on bleeding events.
He added that HMB-003 is a non-hormonal, selective antifibrinolytic designed to protect menstrual cycles before clearing from the body between cycles.
Priyanka Raheja, consultant hematologist at Barts Health NHS Trust, said the data support a non-replacement approach in VWD.
She noted that a single subcutaneous dose increased both Von Willebrand factor (VWF) and Factor VIII (FVIII) by more than two-fold while maintaining a favorable safety profile across all study cohorts.
Raheja said the therapy has the potential to address the underlying cause of VWD by delivering a durable increase in VWF and FVIII levels.
Clinical Findings Support Monthly Dosing Potential
Recently listed, Hemab said pharmacokinetic analyses showed dose-dependent increases in drug exposure with an extended half-life.
In the 150 mg cohort, HMB-002 increased both VWF and FVIII by at least 2.4-fold while restoring thrombin generation, shortening activated partial thromboplastin time (APTT), and maintaining stable multimer distribution. The pharmacokinetic and pharmacodynamic profile supports the potential for monthly dosing.
The company also reported that most treatment-emergent adverse events were mild to moderate.
Although the single ascending dose study was not designed to evaluate efficacy, Hemab said eight of nine evaluable patients experienced no treated bleeding events during the 28 days after receiving HMB-002.
Participants had a baseline mean annualized treated bleeding rate (ATBR) of 20.1 before treatment, reflecting the disease burden associated with Type 1 VWD.
Hemab Expands Pipeline With HMB-003
Hemab also introduced HMB-003, a fatty-acid-conjugated peptide antifibrinolytic designed to stabilize blood clots and reduce bleeding, initially focusing on heavy menstrual bleeding.
Preclinical data showed that HMB-003 selectively inhibits plasmin while preserving thrombin generation, platelet function, and coagulation.
In minipig studies, a single subcutaneous dose maintained antifibrinolytic activity for approximately one week, supporting the potential for cycle-matched dosing in heavy menstrual bleeding.
COAG Stock Price Activity: Hemab Therapeutics shares were up 6.42% at $40.47 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
Login to comment